NHS Dudley Health Economy Medicines Formulary
Home > 8 Malignant disease and immunosuppression > 8.1 Cytotoxic drugs > 8.1.5 Other antineoplastic drugs > Breast cancer (early) - docetaxel - NICE TAG TA109

Breast cancer (early) - docetaxel - NICE TAG TA109

This guidance replaces paragraph 1.3 of Taxanes for the treatment of breast cancer (NICE technology appraisal guidance 30) issued in September 2001 [Replaced by NICE clinical guideline 81].

CG80 Early and locally advanced breast cancer updates the recommendations contained in this appraisal.

For details, see 'About this guidance'.

1.1 Docetaxel, when given concurrently with doxorubicin and cyclophosphamide (the TAC regimen) as per its licensed indication, is recommended as an option for the adjuvant treatment of women with early node-positive breast cancer.



Site by Devopa
© Copyright 2024 NHS. All rights reserved.